ALPS Advisors’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.52M | Buy |
7,786
+2,613
| +51% | +$542K | 0.01% | 593 |
|
|
2026
Q1 | $1.16M | Buy |
5,173
+109
| +2% | +$27.2K | 0.01% | 556 |
|
|
2025
Q4 | $1.22M | Buy |
5,064
+224
| +5% | +$57.3K | 0.01% | 492 |
|
|
2025
Q3 | $1.32M | Sell |
4,840
-148
| -3% | -$40.4K | 0.01% | 461 |
|
|
2025
Q2 | $1.29M | Sell |
4,988
-399
| -7% | -$95.2K | 0.01% | 449 |
|
|
2025
Q1 | $1.21M | Buy |
5,387
+117
| +2% | +$27.3K | 0.01% | 435 |
|
|
2024
Q4 | $1.21M | Buy |
5,270
+292
| +6% | +$70.3K | 0.01% | 443 |
|
|
2024
Q3 | $1.22M | Sell |
4,978
-1,954
| -28% | -$437K | 0.01% | 453 |
|
|
2024
Q2 | $1.33M | Sell |
6,932
-835
| -11% | -$169K | 0.01% | 405 |
|
|
2024
Q1 | $1.54M | Buy |
7,767
+1,418
| +22% | +$260K | 0.01% | 393 |
|
|
2023
Q4 | $1.09M | Sell |
6,349
-401
| -6% | -$61.6K | 0.01% | 452 |
|
|
2023
Q3 | $998K | Buy |
6,750
+64
| +1% | +$11.6K | 0.01% | 446 |
|
|
2023
Q2 | $1.46M | Sell |
6,686
-366
| -5% | -$81.6K | 0.01% | 380 |
|
|
2023
Q1 | $1.54M | Buy |
7,052
+605
| +9% | +$131K | 0.01% | 355 |
|
|
2022
Q4 | $1.34M | Sell |
6,447
-355
| -5% | -$78K | 0.01% | 384 |
|
|
2022
Q3 | $1.49M | Buy |
6,802
+218
| +3% | +$49.6K | 0.01% | 363 |
|
|
2022
Q2 | $1.38M | Sell |
6,584
-372
| -5% | -$79.2K | 0.01% | 384 |
|
|
2022
Q1 | $1.69M | Sell |
6,956
-2,184
| -24% | -$528K | 0.02% | 256 |
|
|
2021
Q4 | $2.38M | Buy |
9,140
+834
| +10% | +$216K | 0.03% | 262 |
|
|
2021
Q3 | $2.19M | Sell |
8,306
-3,618
| -30% | -$989K | 0.02% | 303 |
|
|
2021
Q2 | $2.94M | Sell |
11,924
-978
| -8% | -$206K | 0.03% | 218 |
|
|
2021
Q1 | $2.5M | Buy |
12,902
+3,368
| +35% | +$675K | 0.02% | 245 |
|
|
2020
Q4 | $2.03M | Buy |
9,534
+1,192
| +14% | +$238K | 0.02% | 271 |
|
|
2020
Q3 | $1.43M | Buy |
8,342
+7,086
| +564% | +$1.31M | 0.02% | 283 |
|
|
2020
Q2 | $241K | Sell |
1,256
-138
| -10% | -$22.6K | ﹤0.01% | 678 |
|
|
2020
Q1 | $205K | Sell |
1,394
-1,217
| -47% | -$194K | ﹤0.01% | 759 |
|
|
2019
Q4 | $405K | Sell |
2,611
-114
| -4% | -$16.4K | ﹤0.01% | 565 |
|
|
2019
Q3 | $368K | Buy |
+2,725
| New | +$357K | ﹤0.01% | 565 |
|
|
2017
Q1 | – | Sell |
-6,377
| Closed | -$396K | – | 817 |
|
|
2016
Q4 | $396K | Sell |
6,377
-139
| -2% | -$8.51K | ﹤0.01% | 599 |
|
|
2016
Q3 | $422K | Sell |
6,516
-248
| -4% | -$16.5K | ﹤0.01% | 467 |
|
|
2016
Q2 | $428K | Sell |
6,764
-496
| -7% | -$29.2K | ﹤0.01% | 382 |
|
|
2016
Q1 | $420K | Sell |
7,260
-2,565
| -26% | -$145K | ﹤0.01% | 532 |
|
|
2015
Q4 | $528K | Hold |
9,825
| – | – | 0.01% | 374 |
|
|
2015
Q3 | $5.01K | Buy |
9,825
+2,374
| +32% | +$128K | 0.01% | 363 |
|
|
2015
Q2 | $420K | Buy |
7,451
+116
| +2% | +$7.32K | ﹤0.01% | 619 |
|
|
2015
Q1 | $527K | Sell |
7,335
-2,822
| -28% | -$183K | ﹤0.01% | 412 |
|
|
2014
Q4 | $569K | Sell |
10,157
-1,466
| -13% | -$76.6K | ﹤0.01% | 338 |
|
|
2014
Q3 | $573K | Sell |
11,623
-1,790
| -13% | -$91.2K | ﹤0.01% | 426 |
|
|
2014
Q2 | $679K | Buy |
13,413
+344
| +3% | +$17K | 0.01% | 226 |
|
|
2014
Q1 | $584K | Buy |
13,069
+3,967
| +44% | +$178K | 0.01% | 340 |
|
|
2013
Q4 | $397K | Buy |
9,102
+4,410
| +94% | +$223K | ﹤0.01% | 532 |
|
|
2013
Q3 | $248K | Buy |
+4,692
| New | +$228K | ﹤0.01% | 471 |
|
Other funds holding RMD
ALPS Advisors's RMD Position: Q2 2026 in Review
ALPS Advisors increased its ResMed (RMD) stake by 51% in Q2 2026, buying an estimated $542K and bringing the position to 7,786 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #593.
ALPS Advisors first reported a position in RMD in Q3 2013 and has held it in 42 quarters since. The position peaked at $2.94M in Q2 2021. 448 funds tracked by Wall St. Rank hold RMD as of Q2 2026.
- ALPS Advisors held 7,786 shares of ResMed worth $1.52M as of Q2 2026.
- ALPS Advisors bought 2,613 ResMed shares in Q2 2026, an estimated $542K.
- ResMed made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #593 holding.
- ALPS Advisors first reported a position in ResMed in Q3 2013 and has held it in 42 quarters since.
- ALPS Advisors's ResMed position peaked at $2.94M in Q2 2021.
- 448 funds tracked by Wall St. Rank held ResMed as of Q2 2026.
Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.